**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 66162

**Manuscript Type:** CASE REPORT

**Surgical treatment of liver metastasis with uveal melanoma: A case report**

Kim YH *et al*. Malignant melanoma liver metastasis

Young-Hun Kim, Nam-Kyu Choi

**Young-Hun Kim,** Department ofSurgery, Chosun University Hospital, Gwangju Metropolitan City 61453, South Korea

**Nam-Kyu Choi,** Department of Surgery, Division of Hepatobiliary Surgery and Liver Transplantation, Chosun University Hospital, Gwangju Metropolitan City 61453, South Korea

**Author contributions:** Kim YH collected the clinical information and drafted the manuscript; Choi NK reviewed the literature and contributed to manuscript revision; both authors contributed to intellectual discussions regarding the manuscript content and approved the final manuscript to be submitted.

**Corresponding author: Nam-Kyu Choi, MD, Professor,** Department of Surgery, Division of Hepatobiliary Surgery and Liver Transplantation, Chosun University Hospital, 365 Pilmun-daero, Seonam-dong, Dong-gu, Gwangju Metropolitan City 61453, South Korea. cnk@chosun.ac.kr

**Received:** May 19, 2021

**Revised:** June 27, 2021

**Accepted:** July 30, 2021

**Published online:** October 6, 2021

**Abstract**

BACKGROUND

Uveal melanoma is the most common primary intraocular malignant tumor affecting the eyes in adults. Nearly half of all primary uveal melanoma tumors metastasize; yet, there are currently no effective treatments for metastatic uveal melanoma. At the time of diagnosis, less than 4% of patients with uveal melanoma have detectable metastatic disease. Uveal melanoma disseminates hematogenously, with the most common site of metastasis being liver (93%), followed by lung (24%) and bone (16%).

CASE SUMMARY

A 57-year-old woman was diagnosed with a dysplastic nevus on her eyelid, which was histologically confirmed as malignant melanoma after resection. The patient had no evidence of metastasis to other organs and received both radiation therapy and chemotherapy. After systemic treatment, a metastatic left neck lymph node was found and another round of chemotherapy was performed after resection. Positron emission tomography-Computed Tomography tracking after completion of chemotherapy revealed two metastatic liver nodules. The patient underwent partial liver resection and showed no signs of recurrence at 1 year after surgery.

CONCLUSION

Surgery is an effective treatment for metastatic uveal melanoma. In patients with liver metastatic lesions, hepatectomy improves outcome.

**Key Words:** Uveal melanoma; Metastatic melanoma; Liver metastasis; Hepatectomy; Prognosis; Case report

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Kim YH, Choi NK. Surgical treatment of liver metastasis with uveal melanoma: A case report. *World J Clin Cases* 2021; 9(28): 8498-8503

URL: https://www.wjgnet.com/2307-8960/full/v9/i28/8498.htm

DOI: https://dx.doi.org/10.12998/wjcc.v9.i28.8498

**Core Tip:** Uveal melanoma is the most common primary intraocular malignant tumor affecting the eyes in adults. Nearly half of all primary uveal melanoma tumors metastasize; yet, there are currently no effective treatments for metastatic uveal melanoma. We reported a case of malignant melanoma. We found that the surgical approach to treatment of uveal melanoma with liver metastases improves prognosis.

**INTRODUCTION**

Uveal melanoma is the most common primary intraocular malignant tumor affecting the eyes in adults[1]. While this type of melanoma can affect any part of the uveal tract, the choroid is predominant (86.3%), whereas iris and ciliary body are far less frequently involved[2]. Most patients with uveal melanoma are between 50 and 80 years of age, with the peak occurrence in the 70s[1] and a mean age of 58 years at the time of diagnosis[3]. Exposure to solar ultraviolet radiation is a well-known risk factor for the development of cutaneous melanoma, but evidence of its role in the development of uveal melanoma is inconclusive[4]. Other possible etiological factors include fair skin and oculodermal melanocytosis[5,6].

Because of the lack of lymphatics in the eye itself, uveal melanoma disseminates hematogenously, showing a high propensity for the liver, which accounts for 93% of cases of metastases, followed by the lungs (24%) and bones (16%). It can also metastasize to the brain, skin, and other sites. Indeed, most patients with metastatic disease have metastases at multiple sites[7]. Recent efforts to reduce mortality caused by metastatic uveal melanoma have not been successful. Survival in the presence of metastatic disease is 2–7 mo, depending on the treatment method, and the 1-year overall survival is low, ranging from 13%-29%. The most common contributors to negative prognosis are an age of more than 60 years, male sex, a short interval between primary diagnosis and manifestation of first metastases, and multiple liver metastases[8,9].

Metastatic uveal melanoma requires complex therapy. Treatment most often includes systemic chemotherapy (*e.g*., dacarbazine or fotemustine) and immunotherapy[9]. However, treatment is complicated by the presence of isolated liver metastases, which necessitate surgery and chemoembolization[8,10].

**CASE PRESENTATION**

***Chief complaints***

A 57-year-old woman was admitted for treatment of liver nodules. Three years prior, she had been diagnosed with histologically-confirmed uveal melanoma in the left eye and had been treated with chemotherapy after undergoing resection of the affected eye and upper and lower eyelids. At her 3-year follow-up, metastatic lesions were found on the liver *via* positron emission tomography (PET) and computed tomography (CT).

***History of present illness***

Originally, the patient had visited the outpatient ophthalmology clinic with complaint of left eyeball discomfort. In May 2011, the patient had been diagnosed with dysplastic nevus. Accordingly, a mass was removed from the left eye and confirmed by histology as malignant melanoma (Figure 1A); the patient underwent subsequent treatment by radiotherapy (total 6400 cGY, 32 wk) and chemotherapy (single-agent dacabazine 150 mg/m2 daily for 5 d every 4 wk, four rounds). In December 2012, she underwent total exenteration of the left eye for local invasion of the melanoma (Figure 2), and a follow-up PET-CT revealed metastases in the left jugular lymph nodes. In March 2013, a left radical neck lymph node dissection was performed, after which the patient underwent chemotherapy with high-dose interferon (IFN)-alpha administered on a 2-d interval schedule for 48 wk. Neither abdominal nor thoracic CT showed metastatic lesions in the solid organs or ascites. In June 2014, the patient completed IFN-alpha chemotherapy, but follow-up PET-CT in July 2014 revealed two metastatic nodules in the right lobe of the liver, being 2.5 cm (segment #7) and 2.3 cm (segment #5) in size (Figure 3).

***History of past illness***

The patient did not have any underlying disease.

***Personal and family history***

The patient had no notable family or personal history.

***Physical examination***

The patient had no unusual abdominal symptoms.

***Laboratory examinations***

The whole blood count, serum electrolyte levels, liver function test results, urea nitrogen level, creatinine level, and C-reactive protein level were normal.

***Imaging examinations***

Serial PET-CT found hypermetabolic sites. In December 2011, a PET-CT had revealed the metastatic lesion in the left eyelid, and metastases had been detected in the left jugular lymph nodes in December 2012. In June 2014, the follow-up PET-CT revealed two metastatic nodules in the right lobe of the liver (2.5 cm in segment #7 and 2.3 cm in segment #5) (Figure 3).

**FINAL DIAGNOSIS**

The clinical features and radiological findings supported a diagnosis of liver metastasis from uveal melanoma.

**TREATMENT**

The patient underwent partial hepatectomy with the removal of segments #5 and #7 of the liver in July 2014 (Figure 4). Histological findings confirmed metastatic malignant melanoma, with clear resection margins and no lymphovascular invasion (Figure 1B).

**OUTCOME AND FOLLOW-UP**

The patient was discharged without postoperative complications. She had no signs of recurrence in the liver 3 mo later on abdominal CT and at 12 mo postoperative on PET-CT. She was lost to follow-up at 18 mo because she did not want any further follow-up care.

**DISCUSSION**

We report a case of surgical treatment for uveal melanoma with liver metastasis. The patient was first diagnosed with uveal melanoma in December 2012 and received systemic dacabazine chemotherapy. One year later, she underwent cervical lymph node removal and received IFN-alpha chemotherapy. In July 2014, we detected liver metastasis, and performed a partial hepatectomy. After surgery, she received dacabazine chemotherapy. Although the follow-up had been cut off after 18 mo of chemotherapy, the outcome to that point was good.

The patient had a positive prognosis because she was younger than 60 years of age, female, and had a low-severity liver metastatic burden (Eastern Cooperative Oncology Group performance status 0, normal ranges on liver function tests). Negative prognosis factors for her, however, were the short interval between uveal melanoma diagnosis and the diagnosis of multiple liver metastases. We performed a hepatectomy based on the patient’s performance status and absence of signs of distant metastasis. The results were satisfactory in that the metastatic lesion was removed with clear resection margins and no lymphovascular invasion was detected.

In a large study that enrolled 602 patients with primary uveal melanoma, Kodjikian *et al*[9] reported that complete surgical removal of metastases with postoperative intra-arterial chemotherapy was more effective for prolonging survival than partial removal of metastases along with postoperative intra-arterial chemotherapy or best supportive care. Other studies have demonstrated that radical resection of up to four to five liver metastases without signs of micrometastases may improve the prognosis of metastatic disease[11]. A French study of 3873 patients with uveal melanoma, including 798 who developed liver metastases, found that time to diagnosis of liver metastasis (< 24 mo after primary diagnosis), nonradical resection of liver metastases (R1–2), more than four liver metastases, and confirmed miliary metastases were all negatively associated with overall survival[12]. Close follow-up of all patients with uveal melanoma is recommended to detect possible metastases at the earliest possible time. Prompt detection of metastasis allows for surgical resection and systemic treatment aimed at complete regression.

As liver metastases are usually hypervascular, chemoembolization or intra-arterial chemotherapy are effective treatments. The reported response rate to chemoembolization is 36%, but survival benefits similar to those of systemic chemotherapy have not been reported[13]. Dacarbazine, cisplatin, fotemustine, or their combinations are frequently used in chemoembolization and intra-arterial chemotherapy[9,13,14]. In our case, the patient was given four courses of systemic single-agent dacarbazine chemotherapy and a 52-wk course of IFN-alpha.

Although we removed the metastatic lesions from the liver and there were no signs of recurrence in our patient, regular follow-up and evaluation should be performed in cases of malignancies to obtain the best possible survival outcomes.

**CONCLUSION**

This article reports on the successful surgical treatment of liver metastasis from uveal melanoma. Uveal melanoma itself has a poor prognosis, especially if metastasis is involved. For metastatic melanoma, liver resection may be a good option if liver metastases develop despite systemic treatment. Careful selection and implementation of an optimal treatment plan, within a timely manner, are required to achieve the best outcome for patients with uveal melanoma liver metastasis.

**REFERENCES**

1 **Bedikian AY**. Metastatic uveal melanoma therapy: current options. *Int Ophthalmol Clin* 2006; **46**: 151-166 [PMID: 16365561 DOI: 10.1097/01.iio.0000195852.08453.de]

2 **McLaughlin CC**, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. *Cancer* 2005; **103**: 1000-1007 [PMID: 15651058 DOI: 10.1002/cncr.20866]

3 **Shields CL**, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade OA, Mehta S, Forte L, Long A, Dellacava EF, Kaplan B, Shields JA. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. *Arch Ophthalmol* 2009; **127**: 989-998 [PMID: 19667335 DOI: 10.1001/archophthalmol.2009.208]

4 **Jovanovic P**, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. Ocular melanoma: an overview of the current status. *Int J Clin Exp Pathol* 2013; **6**: 1230-1244 [PMID: 23826405]

5 **Schmidt-Pokrzywniak A**, Jöckel KH, Bornfeld N, Sauerwein W, Stang A. Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: a case-control study. *Ophthalmology* 2009; **116**: 340-348 [PMID: 19091418 DOI: 10.1016/j.ophtha.2008.09.040]

6 **Singh AD**, De Potter P, Fijal BA, Shields CL, Shields JA, Elston RC. Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis. *Ophthalmology* 1998; **105**: 195-198 [PMID: 9442799 DOI: 10.1016/s0161-6420(98)92205-9]

7 **Collaborative Ocular Melanoma Study Group**. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. *Arch Ophthalmol* 2001; **119**: 670-676 [PMID: 11346394 DOI: 10.1001/archopht.119.5.670]

8 **Aoyama T**, Mastrangelo MJ, Berd D, Nathan FE, Shields CL, Shields JA, Rosato EL, Rosato FE, Sato T. Protracted survival after resection of metastatic uveal melanoma. *Cancer* 2000; **89**: 1561-1568 [PMID: 11013372 DOI: 10.1002/1097-0142(20001001)89:7<1561::aid-cncr21>3.0.co;2-r]

9 **Kodjikian L**, Grange JD, Baldo S, Baillif S, Garweg JG, Rivoire M. Prognostic factors of liver metastases from uveal melanoma. *Graefes Arch Clin Exp Ophthalmol* 2005; **243**: 985-993 [PMID: 15891893 DOI: 10.1007/s00417-005-1188-8]

10 **Frenkel S**, Nir I, Hendler K, Lotem M, Eid A, Jurim O, Pe'er J. Long-term survival of uveal melanoma patients after surgery for liver metastases. *Br J Ophthalmol* 2009; **93**: 1042-1046 [PMID: 19429579 DOI: 10.1136/bjo.2008.153684]

11 **Brasiuniene B**, Sokolovas V, Brasiunas V, Barakauskiene A, Strupas K.Combined treatment of uveal melanoma liver metastases. *Eur J Med Res* 2011; **16**: 71-75 [PMID: 21463985 DOI: 10.1186/2047-783X-16-2-71]

12 **Mariani P**, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, Couturier J, Levy-Gabriel C, Lumbroso-Le Rouic L, Desjardins L, Salmon RJ. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. *Eur J Surg Oncol* 2009; **35**: 1192-1197 [PMID: 19329272 DOI: 10.1016/j.ejso.2009.02.016]

13 **Rivoire M**, Kodjikian L, Baldo S, Kaemmerlen P, Négrier S, Grange JD. Treatment of liver metastases from uveal melanoma. *Ann Surg Oncol* 2005; **12**: 422-428 [PMID: 15886904 DOI: 10.1245/ASO.2005.06.032]

14 **Huppert PE**, Fierlbeck G, Pereira P, Schanz S, Duda SH, Wietholtz H, Rozeik C, Claussen CD. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. *Eur J Radiol* 2010; **74**: e38-e44 [PMID: 19467811 DOI: 10.1016/j.ejrad.2009.03.064]

**Footnotes**

**Informed consent statement:** The patient provided informed written consent for reporting of her case and accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**CARE Checklist (2016) statement:** The authors have read the 2016 CARE Checklist (2016), and the manuscript was prepared and revised according to the 2016 CARE Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** May 19, 2021

**First decision:** June 15, 2021

**Article in press:** July 30, 2021

**Specialty type:** Surgery

**Country/Territory of origin:** South Korea

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Buiar PG, Takemura N **S-Editor:** Yan JP **L-Editor:** A **P-Editor:** Wang LYT

**Figure Legends**

**A B**

****

**Figure 1 Histology of malignant melanoma.** A: Eyelid tissue; B: Liver tissue.

****

**Figure 2 Macroscopic appearance of the uveal melanoma affecting the left eye and eyelid.**

****

**Figure 3 Computed Tomography images of the liver showing multiple liver metastases.** Representative images.



**Figure 4 Macroscopic appearance of liver segments with pigmented deposits of metastatic uveal melanoma.**



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**